evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 2 · 28.6%Very low 0 · 0%Low 5 · 71.4%Moderate 0 · 0%High 0 · 0%

Omega‐3 vs placebo

Mental state: psychotic symptoms Average total score (PANSS, higher score = worse, scale from 30‐210) Long‐term (up to 7 years) · people in the prodromal stage of psychosis
1 finding from 1 review

Omega‐3 vs placebo

Adverse effects: neurological, extrapyramidal UKU (events) Medium‐term · people in the prodromal stage of psychosis

Group A: omega‐3 fatty acids showed no clear difference in adverse effects: neurological, extrapyramidal UKU (events) Medium‐term compared with placebo (low certainty).

1 finding from 1 review

Omega‐3 vs placebo

Satisfaction with treatment: 1. Leaving the study early ‐ long term · people in the prodromal stage of psychosis

Group A: omega‐3 fatty acids showed no clear difference in satisfaction with treatment: leaving the study early Long‐term… compared with placebo (low certainty).

1 finding from 1 review

Omega‐3 vs placebo

Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis

Group A: omega‐3 fatty acids may leads to lower prodromal symptoms: transition to psychosis Long‐term (events) compared with placebo (low certainty).

1 finding from 1 review

Omega‐3 vs placebo

Global state: antipsychotic prescription Long‐term (events) · people in the prodromal stage of psychosis

Group A: omega‐3 fatty acids may leads to lower global state: antipsychotic prescription Long‐term (events) compared with placebo (low certainty).

1 finding from 1 review